Table 2.
Intermediate Risk Disease (IR)
| IR | Type of the study | Study years |
Number of patients |
Median FU in years |
Sub Group Risk stratification |
Treatment | % on ADT |
Median ADT duration |
Overall bPFS |
ADT benefit to bPFS |
Overall CSS |
ADT benefit to CSS |
Overall OS |
ADT benefit to OS |
Comments/factors Predictive of outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LDR | |||||||||||||||
| Rosenberg (75) | Chicago | 1997-2007 | 807 | 4.5y (IQR2.7-6.2y) | NR | LDR±ADT or EBRT+LDR | 76% | 4mo (2-6 mo) | NR | NR | 98% | Benefit to ADT (2%) | NR | NR | PCSM (3.3 vs 1.1% EBRT+PB vs PB+ ADT) CSS (iPSA, GS4+3, no ADT) |
| Tran (76) | Multiinstitutional UK | 2003-2007 | 615 | 5y (0.3-8.3y) | NR | LDR±ADT | 17% | 4mo | 88% | No benefit | NR | NR | NR | NR | bPFS (iPSA) |
| Ho (77) | Mount Sinai NY 2009 | 1990-2004 | 558 | 5y | 1 IRF: 68% 2 IRF: 26% 3 IRF: 5% |
LDR±EBRT±ADT | 74% | 3-9 mo | 86% | No benefit | NR | NR | NR | NR | bPFS (BED <150Gy2, 10% benefit to ADT, p=ns) |
| Keane (78) | Harvard Boston MA | 1997-2013 | 2510 | 7,8y (IQR5.3-10.5) | fIR: 76% uIR: 24% |
LDR±ADT, or EBRT+LDR | 33% | 4mo | NR | NR | NR | Benefit ADT only in unfavourable IR (HR 0.34 CI .13-.91) | NR | NR | CSS (Year of PB, ADT (uIR and risk stratification) |
| Bittner (79) | Multiinstitutional US | 1995-2001 | 932 | 7,4y | 90%IR GS 3+4: 58% GS 4+3: 41% |
LDR+EBRT,±ADT | 29% | 6mo | 95% | No benefit | 98% | No benefit | 77% | No benefit | bPFS (GS, iPSA, stage) CSS(nil) OS(age, diabetes, tobacco, CAD) |
| Stock (80) | Mount Sinai NY | 1994-2006 | 432 | 4,6y (23-155 mo) | 1 IRF: 47% 2IRF: 41% 3IRF: 12% |
LDR+EBRT±ADT | 81% | 4mo (324) | 92% | No benefit | NR | NR | NR | NR | bPFS(iPSA, GS, CS, number of risk features) |